Miceli Sopo S, Monaco S, Greco M, Onesimo R
Department of Paediatrics, Catholic University of Sacred Heart, Policlinic A. Gemelli, Rome, Italy.
Department of Paediatrics, Catholic University of Sacred Heart, Policlinic A. Gemelli, Rome, Italy.
Allergol Immunopathol (Madr). 2016 Jan-Feb;44(1):54-8. doi: 10.1016/j.aller.2015.04.010. Epub 2015 Aug 1.
After a passed oral food challenge (OFC), regular and normal food consumption is attended. The main objective of this study is to assess the safety of tested food dietary re-introduction after a passed OFC.
In 2014, a telephone survey was submitted to patients who passed OFC and those who failed it only presenting with contact urticaria (we consider these OFC as passed), between 2009 and 2013. Questionnaire items included demographic data, food allergy details, food consumption after the OFC was performed, recurring symptoms and life style changes.
249 OFC questionnaires were collected from 199 children, 228 OFC were passed, 21 were failed exclusively due to contact urticaria. The most tested food was cows' milk. In 71% of cases target food was re-introduced in patients diet in normal amounts. We found children >2 years introduced less frequently tested food than infants. In 2% of cases adverse reactions to offending food were reported, but severe reactions never occurred.
The majority of children of this study ate target food regularly and their family's quality of life improved. In our study, adverse reactions frequency in patients who passed OFC was very low and never serious. We highlight the importance of re-assessing proper food consumption in every patient who passed OFC.
在口服食物激发试验(OFC)通过后,可恢复正常规律的食物摄入。本研究的主要目的是评估口服食物激发试验通过后重新引入受试食物饮食的安全性。
2014年,对2009年至2013年间口服食物激发试验通过的患者以及仅出现接触性荨麻疹而试验失败的患者(我们将这些口服食物激发试验视为通过)进行了电话调查。问卷项目包括人口统计学数据、食物过敏详情、口服食物激发试验后的食物摄入情况、复发症状和生活方式改变。
从199名儿童中收集了249份口服食物激发试验问卷,228份口服食物激发试验通过,21份仅因接触性荨麻疹而失败。受试最多的食物是牛奶。在71%的病例中,目标食物以正常量重新引入患者饮食。我们发现,2岁以上儿童引入受试食物的频率低于婴儿。在2%的病例中报告了对致敏食物的不良反应,但从未发生严重反应。
本研究中的大多数儿童定期食用目标食物,其家庭生活质量得到改善。在我们的研究中,口服食物激发试验通过的患者中不良反应的发生率非常低,且从未严重。我们强调了对每位口服食物激发试验通过的患者重新评估适当食物摄入的重要性。